Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
22.34
-0.10 (-0.45%)
At close: Feb 21, 2025, 4:00 PM
22.33
-0.01 (-0.04%)
After-hours: Feb 21, 2025, 5:02 PM EST
Genmab Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Genmab stock have an average target of 40.71, with a low estimate of 27 and a high estimate of 50. The average target predicts an increase of 82.23% from the current stock price of 22.34.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Genmab stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $27 | Hold → Buy | Upgrades | $27 | +20.86% | Feb 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +123.81% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +123.81% | Jan 8, 2025 |
| BMO Capital | BMO Capital | Buy Reiterates $46 → $48 | Buy | Reiterates | $46 → $48 | +114.86% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +123.81% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
25.57B
from 21.53B
Increased by 18.78%
Revenue Next Year
29.40B
from 25.57B
Increased by 14.98%
EPS This Year
99.27
from 121.36
Decreased by -18.20%
EPS Next Year
127.18
from 99.27
Increased by 28.11%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.6B | 32.9B | 38.2B | ||
| Avg | 25.6B | 29.4B | 33.5B | ||
| Low | 21.9B | 24.2B | 28.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.2% | 28.7% | 29.9% | ||
| Avg | 18.8% | 15.0% | 13.8% | ||
| Low | 1.7% | -5.5% | -4.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 152.45 | 199.07 | 258.39 | ||
| Avg | 99.27 | 127.18 | 165.47 | ||
| Low | 57.17 | 75.96 | 126.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.6% | 100.5% | 103.2% | ||
| Avg | -18.2% | 28.1% | 30.1% | ||
| Low | -52.9% | -23.5% | -0.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.